^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TheraSphere (yttrium 90 microspheres)

    Associations

    News

    Trials
    Company:
    Boston Scientific
    Drug class:
    Beta radiation emitter
    Related drugs:
    Associations

    News

    Trials
    1m
    Yttrium-90 Radiation Segmentectomy for Hepatocellular Carcinoma (clinicaltrials.gov)
    P=N/A, N=64, Not yet recruiting, University of California, San Francisco | Trial completion date: Dec 2028 --> Mar 2029 | Initiation date: May 2026 --> Oct 2026 | Trial primary completion date: Dec 2028 --> Mar 2029
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    TheraSphere (yttrium 90 microspheres)
    1m
    ADVANCE-MCD: A Post Approval Study to Evaluate Safety and Effectiveness of Multicompartmental Dosimetry Planning. (clinicaltrials.gov)
    P=N/A, N=140, Not yet recruiting, Boston Scientific Corporation
    New trial
    |
    TheraSphere (yttrium 90 microspheres)
    2ms
    FRONTIER: A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM (clinicaltrials.gov)
    P1, N=36, Recruiting, Boston Scientific Corporation | Trial primary completion date: Jul 2026 --> Oct 2026
    Trial primary completion date
    |
    TheraSphere (yttrium 90 microspheres)
    2ms
    Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=0, Withdrawn, University of Miami | N=30 --> 0 | Recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    Stivarga (regorafenib) • TheraSphere (yttrium 90 microspheres)
    2ms
    Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial (clinicaltrials.gov)
    P1/2, N=25, Recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Jun 2027 --> Mar 2030 | Trial primary completion date: Jun 2026 --> Mar 2029
    Trial completion date • Trial primary completion date
    |
    TheraSphere (yttrium 90 microspheres)
    2ms
    Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk (clinicaltrials.gov)
    P2, N=200, Recruiting, Northwestern University | Suspended --> Recruiting | N=84 --> 200 | Trial completion date: Jul 2026 --> Jul 2040 | Trial primary completion date: Jul 2026 --> Jul 2040
    Enrollment open • Enrollment change • Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • TheraSphere (yttrium 90 microspheres)
    3ms
    SPLENIC-SIRT: A Study of Selective Internal Radiation Therapy for the Management of Chemotherapy-induced Thrombocytopenia With Splenomegaly in Adult Subjects With Gastrointestinal Cancer (clinicaltrials.gov)
    P=N/A, N=18, Not yet recruiting, Centre Georges Francois Leclerc
    New trial
    |
    TheraSphere (yttrium 90 microspheres)
    3ms
    Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=30, Recruiting, University of Miami | Trial completion date: May 2031 --> Aug 2031 | Trial primary completion date: May 2031 --> Aug 2031
    Trial completion date • Trial primary completion date
    |
    Stivarga (regorafenib) • TheraSphere (yttrium 90 microspheres)
    4ms
    INDIGO: TheraSphere Japan Pre-Market Study (clinicaltrials.gov)
    P=N/A, N=51, Recruiting, Boston Scientific Corporation | Trial completion date: Apr 2027 --> Dec 2027 | Trial primary completion date: Mar 2027 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    TheraSphere (yttrium 90 microspheres)
    4ms
    Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma (clinicaltrials.gov)
    P2, N=30, Recruiting, University of Miami | Trial completion date: Jan 2031 --> May 2031 | Trial primary completion date: Jan 2031 --> May 2031
    Trial completion date • Trial primary completion date
    |
    Stivarga (regorafenib) • TheraSphere (yttrium 90 microspheres)
    5ms
    EMERALD-Y90: A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE (clinicaltrials.gov)
    P2, N=58, Active, not recruiting, AstraZeneca | Trial completion date: Jan 2027 --> Jul 2026 | Trial primary completion date: Oct 2026 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • Imfinzi (durvalumab) • TheraSphere (yttrium 90 microspheres)
    5ms
    ReLIVE: Affordable Made-in-India Microspheres for Liver Cancer Therapy (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Post Graduate Institute of Medical Education and Research, Chandigarh
    New P1 trial
    |
    TheraSphere (yttrium 90 microspheres)